Ilufredo Y Tantoy1, Janine K Cataldo, Bradley E Aouizerat, Anand Dhruva, Christine Miaskowski. 1. Author Affiliations: Department of Physiological Nursing, School of Nursing (Mr Tantoy and Drs Cataldo, Aouizerat, and Miaskowski), School of Medicine (Dr Dhruva), and Institute for Human Genetics (Dr Aouizerat), University of California, San Francisco.
Abstract
BACKGROUND: Patients with colorectal cancer (CRC) rarely experience a single symptom associated with their disease and its treatment. OBJECTIVE: Purpose of this literature review was to summarize the current state of knowledge of multiple co-occurring symptoms in CRC patients who received chemotherapy (CTX) alone or CTX with targeted therapies. METHODS: Comprehensive literature search was conducted from 1990 to 2014. These studies were evaluated in terms of the occurrence of multiple co-occurring symptoms in CRC patients who received CTX alone or CTX with targeted therapies; the most common symptom assessment and quality of life (QOL) instruments used; and the associations identified between select demographic and treatment characteristics, QOL, and multiple co-occurring symptoms. RESULTS: Only 5 studies met this review's inclusion criteria. Two studies compared symptoms in patients who received CTX alone or CTX with targeted therapies, and only 1 study reported on symptom occurrence. Of the 5 studies identified, only 2 used the same instrument to assess symptoms, and only 2 studies evaluated for associations between demographic and treatment characteristics and symptom burden, as well as QOL outcomes. CONCLUSIONS: Given the larger number of patients with CRC, as well as the increased number of CRC patients who will receive targeted therapies with or without CTX, future studies need to describe the occurrence, severity, and distress of multiple co-occurring symptoms and their impact on CRC patients' QOL. IMPLICATIONS FOR PRACTICE: To deliver effective symptom management interventions, the most common, severe, and distressing symptoms that CRC patients experience need to be identified.
BACKGROUND: Patients with colorectal cancer (CRC) rarely experience a single symptom associated with their disease and its treatment. OBJECTIVE: Purpose of this literature review was to summarize the current state of knowledge of multiple co-occurring symptoms in CRC patients who received chemotherapy (CTX) alone or CTX with targeted therapies. METHODS: Comprehensive literature search was conducted from 1990 to 2014. These studies were evaluated in terms of the occurrence of multiple co-occurring symptoms in CRC patients who received CTX alone or CTX with targeted therapies; the most common symptom assessment and quality of life (QOL) instruments used; and the associations identified between select demographic and treatment characteristics, QOL, and multiple co-occurring symptoms. RESULTS: Only 5 studies met this review's inclusion criteria. Two studies compared symptoms in patients who received CTX alone or CTX with targeted therapies, and only 1 study reported on symptom occurrence. Of the 5 studies identified, only 2 used the same instrument to assess symptoms, and only 2 studies evaluated for associations between demographic and treatment characteristics and symptom burden, as well as QOL outcomes. CONCLUSIONS: Given the larger number of patients with CRC, as well as the increased number of CRC patients who will receive targeted therapies with or without CTX, future studies need to describe the occurrence, severity, and distress of multiple co-occurring symptoms and their impact on CRC patients' QOL. IMPLICATIONS FOR PRACTICE: To deliver effective symptom management interventions, the most common, severe, and distressing symptoms that CRC patients experience need to be identified.
Authors: Roxanne E Jensen; Arnold L Potosky; Bryce B Reeve; Elizabeth Hahn; David Cella; James Fries; Ashley Wilder Smith; Theresa H M Keegan; Xiao-Cheng Wu; Lisa Paddock; Carol M Moinpour Journal: Qual Life Res Date: 2015-05-03 Impact factor: 4.147
Authors: Anand Dhruva; Marylin Dodd; Steven M Paul; Bruce A Cooper; Kathryn Lee; Claudia West; Bradley E Aouizerat; Patrick S Swift; William Wara; Christine Miaskowski Journal: Cancer Nurs Date: 2010 May-Jun Impact factor: 2.592
Authors: Jordanka Kirkova; Mellar P Davis; Declan Walsh; Eoin Tiernan; Norma O'Leary; Susan B LeGrand; Ruth L Lagman; K Mitchell Russell Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Ahmet Alacacioglu; Omer Binicier; Ozkan Gungor; Ilhan Oztop; Meliha Dirioz; Ugur Yilmaz Journal: Support Care Cancer Date: 2009-06-25 Impact factor: 3.603
Authors: Maria Tejada; Carol Viele; Kord M Kober; Bruce A Cooper; Steven M Paul; Laura B Dunn; Marilyn J Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Sleep Date: 2019-10-09 Impact factor: 5.849
Authors: Claire J Han; Kerryn Reding; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-08-09 Impact factor: 3.612
Authors: Claire J Han; Kerryn Reding; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Fay Wright; Frances Cartwright; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-05-09 Impact factor: 3.612
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Fay Wright; Laura B Dunn; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-10-17 Impact factor: 3.612
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Kord M Kober; Marilyn J Hammer; Fay Wright; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2021-01-16 Impact factor: 3.359